About us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients’ biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting.

The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company’s shares are listed on AktieTorget (ATORG:SEZI).

Press releases

Notice of Extraordinary General Meeting in Senzime AB (publ)

The shareholders in Senzime AB (publ) reg. no. 556565-5734 (the “Company”) are hereby convened to the extraordinary general meeting at 9.30 (local time) on Friday 3 March 2017 in the premises of Advokatfirman Lindahl at Vaksalagatan 10, 753 20, Uppsala.

Read more

is planning to carry out a fully underwritten rights issue for further market launches and is taking steps toward listing at Nasdaq First North

Uppsala February 16, 2017. The Board of Senzime AB (publ) proposes that an extra general meeting resolves on a rights issue of approximately SEK 24.4 million before issue costs. The rights issue is fully underwritten by the company's principal owner. The proceeds will be used to enable the commercialization of Senzimes products and strengthen its financial position. Concurrently Senzime is planning a listing at Nasdaq First North.

Read more

Senzime signs distribution agreements for the TetraGraph

Uppsala, February 9, 2017. Senzime AB (publ) today announced that it signed exclusive distribution agreements for TetraGraph in the UK, Ireland, Australia and New Zealand.

Read more
See all »

News

Senzime AB (publ) launches new website

Read more

Senzime in the news- Needle-free probe provides information on how organs and tissues recover after surgery

Uppsala BIO and BIO-X writes about Senzime in their news. Senzime has developed an integrated monitoring system that can provide information on the state of a body’s organs. A probe (OnZurf Probe) placed on the tissue surface collects a microdialysis sample that is read by an instrument (CliniSenz Analyzer). Senzime is one of the companies that received funding in the BIO-X call ‘New diagnostic solutions for disease monitoring’.

Read more

Senzime introduces TetraGraph film

Uppsala, October 28, 2016. Senzime proudly presents a new film describing TetraGraph

Read more
See all »